LPCN Short Interest

Lipocine Inc. (LPCN) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $13.2M, listed on NASDAQ, employing roughly 16 people, carrying a beta of 0.50 to the broader market. Lipocine Inc. Led by Mahesh V. Patel, public since 2013-10-22.

Short interest is the total number of shares currently sold short and not yet covered, reported bi-monthly by FINRA. Days to cover (short interest divided by average daily volume) indicates how long it would take short sellers to close positions, with higher values signaling greater squeeze potential.

Settlement Date
2026-05-15
Short Interest
102.1K
Previous Short Interest
173.7K
Change
-41.21%
Days to Cover
1.00
Avg Daily Volume
103.8K
Avg Days to Cover (24 reports)
2.51

Showing 24 bi-monthly FINRA short interest reports for Lipocine Inc..

Learn how short interest is reported and how to read the data →

Frequently asked LPCN short interest questions

What is the current LPCN short interest?
As of the May 15, 2026 settlement, Lipocine Inc. (LPCN) short interest is 102.1K shares, a -41.21% change from the prior period. FINRA publishes short interest twice monthly on the 15th and last business day of each month under Rule 4560.
What is the LPCN days-to-cover ratio?
Days-to-cover is 1.00, calculated as short interest divided by average daily volume. It estimates how many trading days closing all short positions would consume given typical liquidity. Values above 5 days are commonly cited as elevated; values above 10 days are squeeze-relevant.
How does LPCN short interest affect options pricing?
High short interest changes options pricing through three mechanics: borrow-rebate effects (synthetic long stock trades below frictionless put-call parity by approximately the borrow rebate when shares are hard-to-borrow), gamma-squeeze setup risk (if dealers are short gamma against retail call buying, dealer hedge flow can amplify upward moves), and elevated event-vol pricing on names with squeeze potential. See the canonical short-interest documentation for the full mechanism.